Biggest News Aggregation in the World
📰 Evaluating Safety News

Evaluating Safety News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Evaluating Safety. Real-time updates on events, politics, business and more.

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023

– Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Hematologic, Genitourinary, Gastrointestinal, Gynecological and... | May 17, 2023
Foster City United States Domvanalimab Dom Pembrolizumab Pembro Etrumadenant Etruma Axicabtagene Ciloleucel

Tessa Therapeutics Ltd: Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)

Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory CD30-positive lymphomas treated with Tessa's "off the shelf" CD30.CAR
United States Baylor College Of Medicine Kostenloser Wertpapierhandel Ivan Horak Davidh Quach Dave Schemelia

Investegate |Tessa Therapeutics Ltd Announcements | Tessa Therapeutics Ltd: Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)

Investegate announcements from Tessa Therapeutics Ltd, Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)
United States Baylor College Of Medicine Ivan Horak Davidh Quach Dave Schemelia Allogeneic Vsts

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science